文献速递神经儿科影像MR

非增强MRI随访方案对孤立性视路胶质瘤不劣于增强方案

Non-inferiority of a non-gadolinium-enhanced magnetic resonance imaging follow-up protocol for isolated optic pathway gliomas.
PubMed 文献 · Pediatr Radiol · 2021-11-09

本研究为盲法、多读者、非劣效性研究,纳入42例孤立性视路胶质瘤患儿(其中28对检查间尺寸变化)的MRI检查对,比较排除与包含钆对比剂增强序列的两种影像集。7名儿科放射科医生在三次盲法测量中评估肿瘤大小变化,主要终点为轴位交叉乘积测量变化≥25%的读者内一致性,非劣效界值12%。结果显示非增强方案与增强方案的读者内一致性差异为1.2%(95%CI -3.2%至5.5%),证实非增强方案不劣于增强方案。

要点

  • 随访孤立性视路胶质瘤大小变化时,可考虑采用不含钆对比剂的MRI方案。
  • 非增强与增强方案的读者内一致性差异仅1.2%,95%CI上限5.5%低于12%非劣效界值。
  • 测量采用轴位交叉乘积,以≥25%变化作为一致性判断标准。
英文原文(摘要)· 点击展开

BACKGROUND: Pediatric patients with optic pathway gliomas (OPGs) typically undergo a large number of follow-up MRI brain exams with gadolinium-based contrast media (GBCM), which have been associated with gadolinium tissue retention. Therefore, careful consideration of GBCM use in these children is warranted.

OBJECTIVE: To investigate whether GBCM is necessary for OPG MR imaging response assessment using a blinded, non-inferiority, multi-reader study.

MATERIALS AND METHODS: We identified children with OPG and either stable disease or change in tumor size on MRI using a regional cancer registry serving the U.S. Pacific Northwest. For each child, the two relevant, consecutive MRI studies were anonymized and standardized into two imaging sets excluding or including GBCM-enhanced images. Exam pairs were compiled from 42 children with isolated OPG (19 with neurofibromatosis type 1), from a population of 106 children with OPG. We included 28 exam pairs in which there was a change in size between exams. Seven pediatric radiologists measured tumor sizes during three blinded sessions, spaced by at least 1 week. The first measuring session excluded GBCM-enhanced sequences; the others did not. The primary endpoint was intra-reader agreement for ≥ 25% change in axial cross-product measurement, using a 12% non-inferiority threshold.

RESULTS: Analysis demonstrated an overall 1.2% difference (95% confidence interval, -3.2% to 5.5%) for intra-reader agreement using a non-GBCM-enhanced protocol and background variability.

CONCLUSION: A non-GBCM-enhanced protocol was non-inferior to a GBCM-enhanced protocol for assessing change in size of isolated OPGs on follow-up MRI exams.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Maloney, Perez, Iyer, et al. Non-inferiority of a non-gadolinium-enhanced magnetic resonance imaging follow-up protocol for isolated optic pathway gliomas. Pediatr Radiol. 2021. PMID: 34751813. doi:10.1007/s00247-021-05226-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。